Drug resistance is a multifactorial phenomenon that limits the action of antibiotics and chemotherapeutics. Therefore, it is essential to develop new therapeutic strategies capable of inducing cytotoxic effects circumventing chemoresistance. In this regard, the employment of natural and synthetic cationic peptides and polymers has given...
-
2021 (v1)PublicationUploaded on: April 14, 2023
-
2020 (v1)Publication
Human neuroblastoma (NB) is a pediatric tumor, which, after an initial response to therapy, usually develops resistance. Etoposide (ETO) which is a drug commonly used to clinically treat NB, exerts anticancer effects by increasing reactive oxygen species (ROS) generation [1,2]. Similarly, gallic acid (GA), although not specifically in NB...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Aiming at developing a dermal formulation against melanoma, the synthesized imidazo-pyrazoles 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid (3-methoxy-4-phenoxy-benzylidene)-hydrazide (4G) and 2-phenyl-2,3-dihydro-1H-imidazo[1,2-b]pyrazole-7-carboxylic acid (4-benzyloxy-3-methoxy-benzylidene)-hydrazide (4I) were screened on...
Uploaded on: February 13, 2024 -
2023 (v1)Publication
: Neuroblastoma (NB) is a childhood cancer, commonly treated with drugs, such as etopo side (ETO), whose efficacy is limited by the onset of resistance. Here, aiming at identifying new treatments for chemo-resistant NB, the effects of two synthesized imidazo-pyrazoles (IMPs) (4G and 4I) were investigated on ETO-sensitive (HTLA-230) and...
Uploaded on: January 31, 2024 -
2021 (v1)Publication
All-trans-retinoic acid (ATRA) represents the first-choice treatment for several skin diseases, including epithelial skin cancer and acne. However, ATRA's cutaneous side effects, like redness and peeling, and its high instability limit its efficacy. To address these drawbacks and to improve ATRA solubilization, we prepared ATRA-loaded micelles...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
BackgroundMalignant melanoma is the most lethal form of skin cancer which shows BRAF mutation in 50% of patients. In this context, the identification of BRAF(V600E) mutation led to the development of specific inhibitors like PLX4032. Nevertheless, although its initial success, its clinical efficacy is reduced after six-months of therapy leading...
Uploaded on: February 14, 2024 -
2021 (v1)Publication
No description
Uploaded on: April 14, 2023